Half Yearly Report

RNS Number : 4565S
Victrex PLC
19 May 2009
 



                        

19 May 2009

Victrex plc


Results announcement for the six months ended 31 March 2009


  • Group revenue down 31% to £47.4m (2008: £68.5m)

     - underlying revenue down 24% *


  • Group earnings per share down 63% to 8.8p (2008: 23.7p)

     - underlying EPS down 25% *


  • Interim dividend maintained at 5.2p

  • Cash of £14.2m as at 31 March 2009 and no debt (2008: net cash £6.6m)

  • Invibio® operating profit up 47% to £10.4m (2008: £7.1m) 

     - underlying operating profit up 40% *


  • Victrex Polymer Solutions ('VPS') operating profit down 98% to £0.5m (2008: £20.5m) 

     - underlying operating profit down 45% *



* at constant exchange rates and excluding one-off costs



Chairman Anita Frew commented:


'As expected, and as previously reported, Victrex faced a mixed first half. We have continued to see strong progress in Invibio, our biomaterials business, offset by lower volumes in Victrex Polymer Solutions as demand in our major industrial markets remained weak.


April sales volume, at 110 tonnes, has picked up after the fall off in March. Current month order levels are running at a similar level to the same time in April. As previously indicated, for planning purposes, whave assumed that volume will remain at similar levels to the average for the second quarter. Should volume be higher than the second quarter run rate, we will benefit positively from our operational gearing. Furthermore, the underlying growth drivers remain in place across our end use markets and our development pipeline of potential new applications is holding up well. 


Invibio continues to show strong sales performance and development potential. Accordingly, we expect Invibio second half revenue to be maintained at a broadly similar level to the strong first half with further sales growth expected in 2010.'



Enquiries


Victrex plc




David Hummel, Chief Executive

0207 357 9477 (19 May 2009)

Michael PeacockFinance Director

01253 897700 (thereafter)


Hogarth Partnership Limited




Nick Denton / Barnaby Fry

0207 357 9477

  INTERIM MANAGEMENT REPORT


At our Annual General Meeting in February, we announced the strategic reorganisation of our business into two divisions: Invibio®, our biomaterials business and VICTREX PEEK, now known as Victrex Polymer Solutions ('VPS'). Our half year results and reporting now reflect this divisional split.


As expected, and as previously reported, Victrex faced a mixed first half. We have continued to see strong progress in Invibio, offset by lower volumes in VPS as demand in our major industrial markets remained weak.


Group results


At 772 tonnes, first half sales volume was 40% down on the previous first half (1,294 tonnes) because of reduced demand in our major end user industrial markets, particularly automotive and electronics. 


As a result of the significant reduction in sales volume, we have had to buy out surplus forward exchange contracts at a cost of £9.0m for the first half. These contracts were entered into prior to the downturn and in compliance with our currency hedging policy. This adverse impact, which is reflected in reduced revenue, has been partially offset by an improvement in underlying effective exchange rates as remaining sales start to benefit from weaker sterling.


Accordingly, although Group revenue declined by 31% to £47.4m, underlying revenue (at constant exchange rates) was down 24%.


Gross profit decreased by 29% to £31.7m (H1 2008: £44.5m). However, gross margin increased by 2 percentage points to 66.9%, largely as a result of the sales mix effect between Invibio and VPS.


Although sales, marketing and administrative expenses increased by 23% to £21.5m, £2.6of this increase was due to the weakening of sterling in relation to costs incurred in foreign currency and £1.9m related to one-off costs of a streamlining exercise in VPS. Underlying expenses (at constant exchange rates and excluding one-off costs) decreased by 3%.


Group profit before tax decreased by 62% to £10.2m. Exchange rates (including the cost of buying out surplus forward exchange contracts) had a net adverse impact of £8.4m on profit before tax compared to the first half of 2008. Underlying profit at constant exchange rates and excluding one-off costs was £20.5m, a decrease of 25%. Basic earnings per share were down 63% at 8.8p. Underlying earnings per share at constant exchange rates and excluding one-off costs were down 25%.


Cash flow


We continued to generate cash from operations, albeit down at £10.3m in line with the reduction in operating profit. While the effective tax rate remained at 29%, tax paid only decreased to £7.4m (H1 2008: £9.0m) as a significant proportion of the payment related to the 2008 tax charge.


Capital expenditure for the period amounted to £4.3m (H1 2008: £16.0m). We continue to expect total capital expenditure for 2009 to amount to approximately £10m. This is being funded from the Group's cash resources.


Dividend payments for the period (comprising the 2008 final dividend) were £10.8m (H1 2008: £10.3m).


At 31 March 2009, the Group had cash of £14.2m and no debt compared with £6.6m net cash as at 31 March 2008 and £23.5m as at 30 September 2008. The Group has a committed bank facility of £40m, all of which was undrawn as at 31 March 2009. This facility expires in September 2012.


Dividend


While profit and cash flow are down on 2008, the Group remains in a strong cash position. Accordingly, the interim dividend will be maintained at last year's level of 5.2p per share. This will be paid on Tuesday 7 July 2009 to all shareholders on the register at the close of business on Friday 12 June 2009.


Invibio Biomaterials Solutions ('Invibio')



Half year to

31 March 2009

Half year to 

31 March 2008

% change


£m

£m


Revenue

17.6

11.7

+51%

Gross profit

15.4

10.3

+49%

Operating profit

10.4

7.1

+47%


Invibio had an excellent first half and generated record revenue, up 51% on the first half of last year. Underlying revenue (at constant exchange rates) was up 42%.


Sales, marketing and administrative expenses increased by £1.8m to £5.0m, primarily due to increased investment in resources to drive growth in this division. As a result, Invibio employee numbers will increase from 33 as at 30 September 2008 to approximately 45 following completion of the current recruitment programme. We anticipate further growth in commercial and technical roles to meet customer requirements.


Operating profit increased by 47%. Underlying operating profit (at constant exchange rates) amounted to £9.9m, an increase of 40%.


We have continued to make good progress in sales to spinal applications, both in fusion and increasingly in new, non-fusion areas. Other areas of increased revenue included arthroscopy and cranio-maxillo facial ('CMF'). Overall growth continues to be driven by successful commercialisation of new applications. Since the introduction of Invibio's principal biomaterial (PEEK-OPTIMA® polymer) ten years ago, more than two million devices containing PEEK-OPTIMA have been implanted in patients.


Invibio continues to invest in new technologies and developments for medical device manufacturers, as demonstrated by the introduction of MOTIS™ polymer during the American Academy of Orthopedic Surgeons' 2009 Annual Meeting. MOTIS polymer was developed to offer orthopaedic surgeons innovative new options for replacing metal, ceramic and polyethylene components in orthopaedic joint replacements.


Since the start of the new financial year, Invibio has entered into 20 additional PEEK-OPTIMA polymer long-term supply assurance agreements with implantable medical device manufacturers.


Victrex Polymer Solutions ('VPS')



Half year to 

31 March 2009

Half year to 

31 March 2008

% change


£m

£m


Revenue

29.7

56.9

-48%

Gross profit

16.3

34.2

-52%

Operating profit

0.5

20.5

-98%


VPS revenue fell by 48% compared with the first half of 2008, including the £9.0m adverse impact of buying out surplus forward exchange contracts which arose from the significant reduction in VPS sales volume. Underlying revenue (at constant exchange rates) was down 37%.


Although sales, marketing and administrative expenses increased by £2.1m to £15.8m, this included an additional cost of £2.4m due to the weakening of sterling in relation to costs incurred in foreign currency


In addition, we have taken actions to streamline VPS while continuing to invest in new applications and growth areas. As previously announced, we have reduced polymer production levels and have also temporarily suspended BDF monomer production for a period of up to six months. Group staff numbers (excluding Invibio employees) are being reduced, by a combination of leavers not being replaced and a limited redundancy programme, from 486 as at 30 September 2008 to approximately 440 following completion of this exercise, a reduction of just under 10%.


The total one-off cost of this streamlining exercise (reflected in VPS first half sales, marketing and administrative expenses) amounted to £1.9m. Ongoing cost savings are estimated to be £3.6m on an annualised basis. Underlying expenses (at constant exchange rates and excluding one-off costs) were reduced by 16%.


Operating profit decreased by 98%. However, underlying operating profit (at constant exchange rates excluding currency buy out and one-off streamlining costs) amounted to £11.2m, a decrease of 45%.


Major markets


Transport sales volume was 194 tonnes, down 46% on last year's first half of 356 tonnes, principally due to a significant decline in automotive sales in all regions. Aerospace sales were also down but not to the same extent.


Industrial sales volume was 323 tonnes, down 30% on last year's first half of 460 tonnes as oil and gas applications have proved more resilient to the economic downturn.


Electronics sales volume was 139 tonnes, down 54% on last year's first half of 303 tonnes, due to significantly reduced semicon sales and a smaller reduction in consumer electronics sales.


Development pipeline


In spite of the slowdown in sales in the first half we have continued to successfully commercialise new applications, with 267 new VICTREX® PEEKTM polymer applications with an estimated mature annualised volume ('MAV') of 188 tonnes compared with 295 commercialised applications with an estimated MAV of 170 tonnes in the second half of 2008.


With regard to our ongoing development pipeline, as at 31 March 2009, we were working with customers on 2,876 developments (September 2008: 2,978) with an estimated MAV of 2,477 tonnes (September 2008: 2,910 tonnes) if all of the developments were successfully commercialised. As can be seen, we have maintained activity levels, albeit with reduced customer tonnage expectations largely as a result of the economic slowdown.


Risks and uncertainties


Victrex's business and share price may be affected by a number of risks, trends, factors and uncertainties, not all of which are in our control. The process Victrex has in place for identifying, assessing and managing risks is set out in the Corporate Governance Report in the Annual Report and Accounts 2008 on page 22.


The specific principal risks, trends, factors and uncertainties (which could impact the Group's revenues, profits and reputation), which were faced at the time of the last annual report, and relevant mitigating factors as currently identified by Victrex's risk management process, have not changed since the year end. Detailed explanations can be found in the Annual Report and Accounts 2008 on pages 10, 11 and 12. Broadly, these risks include technological change, operational disruption, insufficient capacity, product specifications, competitor activity and currency exposure.


During the period the Group has been impacted by the current economic climate and the measures taken in response, including streamlining the VPS division and reducing production levels, are summarised above. Other risks may also adversely affect the Group. Accordingly, actual results may differ materially from anticipated results because of a variety of risk factors, including: changes in interest and exchange rates; changes in global, political, economic, business, competitive and market forces; changes in raw material pricing and availability; changes to legislation and tax rates; future business combinations or disposals; relations with customers and customer credit risk; events affecting international security, including global health issues and terrorism; changes in regulatory environment, and the outcome of litigation.


Outlook


Trading


April sales volume, at 110 tonnes, has picked up after the fall off in March. Current month order levels are running at a similar level to the same time in April. As previously indicated, for planning purposes, we have assumed that volume will remain at similar levels to the average for the second quarter. Should volume be higher than the second quarter run rate, we will benefit positively from our operational gearing. Furthermore, the underlying growth drivers remain in place across our end use markets and our development pipeline of potential new applications is holding up well. 


Invibio continues to show strong sales performance and development potential. Accordingly, we expect Invibio second half revenue to be maintained at a broadly similar level to the strong first half with further sales growth expected in 2010.


Currency impact and gross margin


As previously reported, trading results for 2009 have been impacted by the cost of buying out surplus currency cover. Based on planned sales volume, hedging already in place and spot exchange rates as at 8 May 2009, we currently estimate the following average rates will apply for the second half:



Half year to 

31 March 2009

Half year to 

30 September 2009


Actual*

Estimate*

US Dollar

2.05

1.87

Euro    

1.38

1.26

Yen    

210

200


* Excluding adverse impact from buy out of surplus forward exchange 

contracts of £9.0m for the first half and £2.3m estimated for the second half.


As a result of these improved rates and materially reduced currency buy out costs, we expect to see a further significant increase in effective sterling average selling price in the second half. However, this will be offset by higher effective fixed production costs per tonne arising principally from reduced production. We therefore expect second half Group gross margin to be approximately 5% points lower than the first half.


Looking ahead to 2010, based on current spot rates and hedging already in place, we expect to see an additional significant increase in effective sterling average selling price, albeit partially offset by further increases in effective fixed production costs per tonne. 


The Company's second interim management statement, covering the period from 1 April 2009, will be issued on Thursday 6 August 2009.


Anita Frew

Chairman

18 May 2009

  CONDENSED CONSOLIDATED INCOME STATEMENT




Unaudited

six months ended

31 March 2009

Unaudited

six months ended

31 March 2008

Audited

year ended

30 September 2008



Note

£000

£000

£000

£000

£000

£000

Revenue

5


47,361


68,508


141,117

Cost of sales



(15,680)


(24,027)


(49,495)

Gross profit

5


31,681


44,481


91,622

Sales, marketing and administrative expenses



(21,511)


(17,504)


(37,041)

Operating profit 

5


10,170


26,977


54,581

Financial income


86


331


577


Financial expenses


(23)


(89)


(127)


Net financing income



63


242


450

Profit before tax



10,233


27,219


55,031

Income tax expense

6


(2,968)


(7,893)


(15,959)

Profit for the period attributable to equity

  shareholders of the parent










7,265


19,326


39,072

















Earnings per share








Basic

7


8.8p


23.7p


47.8p

Diluted

7


8.8p


23.5p


47.4p

Dividends








Year ended 30 September 2007:








  Final dividend paid March 2008 at 12.6p per share



-


10,273


10,273

Year ended 30 September 2008:








  Interim dividend paid July 2008 at 5.2p per share



-


-


4,260

  Final dividend paid February 2009 at 13.1p per share



10,795


-


-


10


10,795


10,273


14,533









An interim dividend of 5.2p per share will be paid on 7 July 2009 to shareholders on the register at the close of business on 12 June 2009This dividend will be recognised in the period in which it is approved.




  CONDENSED CONSOLIDATED BALANCE SHEET 





Unaudited

31 March 2009

Unaudited

31 March 2008

Audited

30 September 2008


Note

£000

£000

£000

Assets





Non-current assets





Property, plant and equipment


130,879

125,291

129,909

Intangible assets


10,568

11,178

10,873

Deferred tax assets


10,631

8,154

8,078



152,078

144,623

148,860

Current assets





Inventories


42,122

28,211

31,675

Current income tax assets


1,066

1,152

244

Trade and other receivables


14,823

18,346

18,195

Derivative financial instruments

8

666

948

855

Cash and cash equivalents


14,223

10,605

23,532



72,900

59,262

74,501

Total assets


224,978

203,885

223,361






Liabilities





Non-current liabilities





Deferred tax liabilities


(15,256)

(13,611)

(14,651)

Retirement benefit obligations


(5,923)

(5,582)

(6,378)



(21,179)

(19,193)

(21,029)

Current liabilities





Derivative financial instruments

8

(23,848)

(12,461)

(10,455)

Short-term borrowings


-

(4,040)

-

Current income tax liabilities


(5,377)

(10,165)

(8,263)

Trade and other payables


(15,866)

(12,893)

(16,820)



(45,091)

(39,559)

(35,538)

Total liabilities


(66,270)

(58,752)

(56,567)






Net assets


158,708

145,133

166,794






Equity





Share capital


830

825

829

Share premium


20,915

19,171

20,723

Translation reserve


4,059

(404)

470

Hedging reserve


(10,945)

(7,441)

(5,570)

Retained earnings


143,849

132,982

150,342

Total equity attributable to equity

  shareholders of the parent

10

158,708

145,133

166,794



 

CONDENSED CONSOLIDATED CASH FLOW STATEMENT





Unaudited

six months ended

31 March 2009

Unaudited

six months ended

31 March 2008

Audited

year ended

30 September 2008


Note

£000

£000

£000

Cash flows from operating activities





Cash generated from operations

11

10,324

27,505

61,858

Interest and similar charges paid


(22)

(120)

(176)

Interest received


86

331

577

Tax paid


(7,360)

(8,995)

(15,703)

Net cash flow from operating activities


3,028

18,721

46,556






Cash flows from investing activities





Acquisition of property, plant and equipment


(4,347)

(15,976)

(25,014)

Net cash flow from investing activities


(4,347)

(15,976)

(25,014)






Cash flows from financing activities





Issue of ordinary shares exercised under option


1

3

7

Premium on issue of ordinary shares exercised

under option


192

1,023

2,575

Purchase of own shares held


(977)

(858)

(858)

Decrease in short-term borrowings


-

-

(4,207)

Dividends paid


(10,795)

(10,273)

(14,533)

Net cash flow from financing activities


(11,579)

(10,105)

(17,016)






Net (decrease)/increase in cash and cash equivalents


(12,898)

(7,360)

4,526

Exchange differences on net investment

  translation of foreign operations


3,589

845

1,886

Cash and cash equivalents at beginning of period


23,532

17,120

17,120

Cash and cash equivalents at end of period


14,223

10,605

23,532


























Components of net cash








Unaudited

31 March 2009

Unaudited

31 March 2008

Audited

30 September 2008



£000

£000

£000

Cash and cash equivalents 


14,223

10,605

23,532

Short-term borrowings


-

(4,040)

-

Net cash 


14,223

6,565

23,532



  CONDENSED CONSOLIDATED STATEMENT OF RECOGNISED INCOME AND EXPENSE





Unaudited

six months ended

31 March 2009

Unaudited

six months ended

31 March 2008

Audited

year ended

30 September 2008


Note

£000

£000

£000

Net change in fair value of cash flow hedges:

  Transferred to equity


(24,310)

(1,639)

(14,509)

  Transferred to income statement


16,845

(8,749)

6,719

Exchange differences on net investment translation 

  of foreign operations


3,589

224

1,098

Actuarial (losses)/gains on defined benefit plans


(1,907)

1,823

867

Tax on items taken directly to or transferred from equity


1,263

2,002

3,238

Net expense recognised directly in equity


(4,520)

(6,339)

(2,587)

Profit for the period


7,265

19,326

39,072

Total recognised income and expense for the period

  attributable to equity shareholders of the parent

10

2,745

12,987

36,485



NOTES TO THE HALF-YEARLY FINANCIAL REPORT


1  Reporting entity


Victrex plc (the 'Company') is a limited liability company incorporated and domiciled in the United Kingdom. The address of the registered office is Victrex Technology Centre, Hillhouse International, Thornton Cleveleys, LancashireFY5 4QD, United Kingdom. The Company is listed on the London Stock Exchange. 


This Half-yearly Financial Report is an interim management report as required by DTR 4.2.3 of the Disclosure and Transparency rules of the UK Financial Services Authority. 


These condensed consolidated interim financial statements as at and for the six months ended 31 March 2009 comprise the Company and its subsidiaries (together referred to as the 'Group'). 


The comparative figures for the financial year ended 30 September 2008 are extracted from the Company's statutory accounts for that year. Those accounts have been reported on by the Company's auditor, filed with the Registrar of Companies and are available on request from the Company's registered office or to download from www.victrex.com. The auditor's report on those accounts was unqualified, did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying their report and did not contain any statement under sections 237(2) or (3) of the Companies Act 1985. 


These condensed consolidated interim financial statements are unaudited, but have been reviewed by KPMG Audit Plc and their report is set out on page 15.



2  Statement of compliance


These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard ('IAS') 34 - Interim Financial Reporting as adopted by the European Union. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the consolidated financial statements of the Group as at and for the year ended 30 September 2008. 


This Half-yearly Financial Report was approved by the Board of Directors on 18 May 2009.



3  Significant accounting policies


The accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied in the Company's published consolidated financial statements for the year ended 30 September 2008 except for the application of relevant new standards. 


Of the new standards, amendments to standards and interpretations which are mandatory for the first time for the year ending 30 September 2009, the only relevant one is IFRIC 14 - IAS 19 - The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction, which is effective for accounting periods commencing on or after 1 January 2008. Whilst the Group is currently assessing the impact, the application of IFRIC 14 is not expected to have a significant impact on the balance sheets or consolidated income statement.


A number of amendments to standards and interpretations have been issued during the period, which are either not yet endorsed or endorsed yet not effective, and accordingly the Group has not yet adopted.



4  Estimates


The preparation of condensed consolidated interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.


The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements as at and for the year ended 30 September 2008.




5  Segment reporting


In the six months ended 31 March 2009, the Group's business was strategically reorganised into two divisions: Invibio and Victrex Polymer Solutions. Consequently, in compliance with IAS 14 - Segmental Reporting, the business will now report divisional information as the primary analysis and geographical information as the secondary analysis.


Primary divisional segments


Results


Unaudited

six months ended 31 March 2009

Unaudited

six months ended 31 March 2008

Audited

year ended 30 September 2008


Victrex

Polymer

Solutions

Invibio

Biomaterials

Solutions

Group

Victrex

Polymer

Solutions

Invibio

Biomaterials

Solutions

Group

Victrex

Polymer

Solutions

Invibio

Biomaterials

Solutions

Group


£000

£000

£000

£000

£000

£000

£000

£000

£000

Total segment sales

32,028

17,630

49,658

56,864

11,650

68,514

117,502

24,900

142,402

Less inter-segment sales

(2,297)

-

(2,297)

(6)

-

(6)

(1,285)

-

(1,285)

Revenue from external sales

29,731

17,630

47,361

56,858

11,650

68,508

116,217

24,900

141,117











Segment gross profit

16,291

15,390

31,681

34,155

10,326

44,481

69,722

21,900

91,622

Sales, marketing and

administrative expenses

(15,812)

(5,015)

(20,827)

(13,704)

(3,251)

(16,955)

(28,618)

(7,404)

(36,022)

Segment operating profit

479

10,375

10,854

20,451

7,075

27,526

41,104

14,496

55,600

Unallocated central costs



(684)



(549)



(1,019)

Operating profit



10,170



26,977



54,581

Net financing income



63



242



450

Profit before tax



10,233



27,219



55,031

Income tax expense



(2,968)



(7,893)



(15,959)

Profit for the period attributable to

equity shareholders of the parent


7,265



19,326



39,072





















Other information










Segment assets

208,629

16,349

224,978

191,950

11,935

203,885

210,193

13,168

223,361

Segment liabilities

62,023

4,247

66,270

51,981

6,771

58,752

52,706

3,861

56,567











Capital expenditure

4,145

106

4,251

15,364

105

15,469

23,365

356

23,721

Depreciation

3,873

108

3,981

3,065

106

3,171

6,786

213

6,999

Amortisation

305

-

305

306

-

306

610

-

610



Secondary geographical segments



Unaudited

six months ended

31 March 2009*

Unaudited

six months ended

31 March 2008

Audited

year ended

30 September 2008


£000

£000

£000

Sales




Europe

22,018

34,239

68,748

USA

23,015

23,974

50,717

Asia-Pacific

2,328

10,295

21,652


47,361

68,508

141,117


Includes the adverse impact from buy out of surplus forward exchange contracts.


6  Taxation


Taxation of profit before tax in respect of the six months ended 31 March 2009 has been provided at the estimated effective rates chargeable for the full year in the respective jurisdiction.



Unaudited

six months ended

31 March 2009

£000

Unaudited

six months ended

31 March 2008

£000

Audited

year ended

30 September 2008

£000

UK corporation taxation

2,760

6,094

9,197

Overseas taxation

872

1,233

3,846

Deferred taxation

(664)

566

2,916


2,968

7,893

15,959



7  Earnings per share



Unaudited

six months ended

31 March 2009

Unaudited

six months ended

31 March 2008

Audited

year ended

30 September 2008

Earnings per share

- basic

8.8p

23.7p

47.8p


- diluted

8.8p

23.5p

47.4p

Profit for the financial period

£7,265,000

£19,326,000

£39,072,000

Weighted average number of shares used

- basic

82,244,501

81,501,608

81,701,581


- diluted

82,567,070

82,098,094

82,355,303



8  Derivative financial instruments


The Group classifies its forward exchange contracts hedging forecast transactions as cash flow hedges and states them at fair value. The notional contract amount, carrying amount and fair value of the Group's forward exchange contracts and swaps designated as cash flow hedges are as follows:



Unaudited

31 March 2009

Unaudited

31 March 2008

Audited

30 September 2008


Notional

contract

amount

Carrying

amount and

fair value

Notional

contract

amount

Carrying

amount and

fair value

Notional

contract

amount

Carrying

amount and

fair value


£000

£000

£000

£000

£000

£000

Current assets

(483)

666

5,176

948

22,594

855

Current liabilities

96,817

(23,848)

134,664

(12,461)

111,966

(10,455)


96,334

(23,182)

139,840

(11,513)

134,560

(9,600)


The fair values have been calculated by applying (where relevant), for equivalent maturity profiles, the rate at which forward currency contracts with the same principal amounts could be acquired at the balance sheet date.


The following table indicates the periods in which cash flows associated with the maturity date of the forward foreign exchange contracts are expected to occur:



Unaudited

31 March 2009

Unaudited

31 March 2008


Expected

cash flows

6 months

or less

6 to 12

months

12 to 18

months

Expected

cash flows

6 months

or less

6 to 12

months

12 to 18

months


£000

£000

£000

£000

£000

£000

£000

£000

Forward exchange contracts

Assets

(483)

(7,080)

2,875

3,722

5,176

4,364

812

-

Liabilities

96,817

46,770

39,879

10,168

134,664

52,450

54,309

27,905


96,334

39,690

42,754

13,890

139,840

56,814

55,121

27,905





Audited

30 September 2008






Expected

cash flows

6 months

or less

6 to 12

months

12 to 18

months






£000

£000

£000

£000

Forward exchange contracts

Assets





22,594

(13,724)

19,646

16,672

Liabilities





111,966

62,796

39,448

9,722






134,560

49,072

59,094

26,394


9  Exchange rates


The most significant sterling exchange rates used in the accounts under the Group's accounting policies are: 



Unaudited

six months ended

31 March 2009

Unaudited

six months ended

31 March 2008

Audited

year ended

30 September 2008


Average*

Closing

Average

Closing

Average

Closing

US Dollar

2.05

1.43

1.98

1.99

1.99

1.78

Euro

1.38

1.08

1.47

1.25

1.47

1.27

Yen

210

142

226

198

229

189


* Excluding adverse impact from buy out of surplus forward exchange contracts.



10  Changes in equity



Unaudited

six months ended

31 March 2009

£000

Unaudited

six months ended

31 March 2008

£000

Audited

year ended

30 September 2008

£000

Equity at beginning of period

166,794

141,483

141,483

Total recognised income and expense

2,745

12,987

36,485

Share options exercised

193

1,026

2,582

Equity-settled share-based payment transactions

748

768

1,635

Purchase of own shares held

(977)

(858)

(858)

Dividends to shareholders

(10,795)

(10,273)

(14,533)

Equity at end of period

158,708

145,133

166,794



11  Reconciliation of profit to cash generated from operations



Unaudited

six months ended

31 March 2009

£000

Unaudited

six months ended

31 March 2008

£000

Audited

year ended

30 September 2008

£000

Profit after tax for the period

7,265

19,326

39,072

Income tax expense

2,968

7,893

15,959

Net financing income

(63)

(242)

(450)

Operating profit 

10,170

26,977

54,581

Adjustments for:




Depreciation

4,178

3,191

7,064

Amortisation

305

306

610

Increase in inventories

(10,447)

(344)

(3,808)

Decrease/(increase) in trade and other receivables

3,372

(2,459)

(2,308)

(Decrease)/increase in trade and other payables

(1,755)

(3,026)

1,466

Equity-settled share-based payment transactions

747

768

1,635

Changes in fair value of derivative financial instruments

6,116

1,797

2,483

Retirement benefit obligations charge less contributions

(2,362)

295

135

Cash generated from operations

10,324

27,505

61,858




12  Related party transactions


The Group's related parties are as disclosed in the Annual Report and Accounts 2008. There were no material differences in related parties or related party transactions in the six months ended 31 March 2009 except for transactions with key management personnel, of which the most significant were as follows:


  • On 12 December 2008, under the 1999 Long Term Incentive Plan ('LTIP'), D R Hummel, M W Peacock, B V Souder and T J Walker exercised 153,774, 100,899, 41,289 and 41,743 share options respectively at an option price of nil p per share when the market price was 444p per share and,


  • On 16 February 2009, under the 2009 LTIP, 92,818, 50,484 and 43,478 share option awards were granted to D R Hummel, M W Peacock and T J Walker respectively at an option price of nil p per share.

  RESPONSIBILITY STATEMENT OF THE DIRECTORS


The Directors confirm that to the best of our knowledge:


  • The condensed consolidated interim financial statements have been prepared in accordance with IAS 34 - Interim Financial Reporting as adopted by the European Union;


  • The Interim Management Report includes a fair review of the information required by:


(a)    DTR 4.2.7R of the Disclosure and Transparency Rules of the Financial Services Authority, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed consolidated financial statements and a description of the principal risks and uncertainties for the remaining six months of the year and,


(b)    DTR 4.2.8R of the Disclosure and Transparency Rules of the Financial Services Authority, being:


i.    related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period and,


ii.    any changes in the related party transactions described in the last Annual Report that have done so.


The Directors of Victrex plc are detailed on page 16 of the Victrex plc Annual Report and Accounts 2008. Since that time the Commercial Director left the Group on 31 March 2009 and this role no longer exists.


By order of the Board



Michael Peacock

Finance Director


18 May 2009


FORWARD-LOOKING STATEMENTS


Sections of this Half-yearly Financial Report contain forward-looking statements, including statements relating to: future demand and markets for the Group's products and services; research and development relating to new products and services, and liquidity and capital resources. These forward-looking statements involve risks and uncertainties because they relate to events that may or may not occur in the future. Accordingly, actual results may differ materially from anticipated results because of a variety of risk factors, including: changes in interest and exchange rates; changes in global, political, economic, business, competitive and market forces; changes in raw material pricing and availability; changes to legislation and tax rates; future business combinations or disposals; relations with customers and customer credit risk; events affecting international security, including global health issues and terrorism; changes in regulatory environment, and the outcome of litigation.


INDEPENDENT REVIEW REPORT TO VICTREX PLC


Introduction

We have been engaged by the Company to review the condensed set of financial statements in the Half-yearly Financial Report for the six months ended 31 March 2009 which comprises the Condensed Consolidated Income Statement, Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Recognised Income and Expense, Condensed Consolidated Cash Flow Statement and the related explanatory notes. We have read the other information contained in the Half-yearly Financial Report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.


This report is made solely to the Company in accordance with the terms of our engagement to assist the Company in meeting the requirements of the Disclosure and Transparency Rules (the 'DTR') of the UK's Financial Services Authority (the 'UK FSA'). Our review has been undertaken so that we might state to the Company those matters we are required to state to it in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company for our review work, for this report, or for the conclusions we have reached.



Directors' responsibilities

The Half-yearly Financial Report is the responsibility of, and has been approved by, the Directors. The Directors are responsible for preparing the Half-yearly Financial Report in accordance with the DTR of the UK FSA. 


As disclosed in note 2, the annual financial statements of the Group are prepared in accordance with IFRSs as adopted by the EU. The condensed set of financial statements included in this Half-yearly Financial Report has been prepared in accordance with IAS 34 - Interim Financial Reporting as adopted by the EU.



Our responsibility

Our responsibility is to express to the Company a conclusion on the condensed set of financial statements in the Half-yearly Financial Report based on our review.



Scope of review

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Auditing Practices Board for use in the UK. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the Half-yearly Financial Report for the six months ended 31 March 2009 is not prepared, in all material respects, in accordance with IAS 34 as adopted by the EU and the DTR of the UK FSA.


Nicola Quayle

For and on behalf of

KPMG Audit Plc,


18 May 2009



SHAREHOLDER INFORMATION


The Company's Annual Reports and Half-yearly Financial Reports are available on request from the Company's registered office or to download from www.victrex.com.



Financial calendar




Ex dividend date for interim dividend 

10 June 2009

Record date for interim dividend* 

12 June 2009

Payment of interim dividend 

7 July 2009

2009 year end 

30 September 2009

Announcement of 2009 full year results 

December 2009

Annual General Meeting 

February 2010

Payment of final dividend 

February 2010


* The date by which shareholders must be recorded on the share register to receive the dividend.



Victrex plc

Registered in England

Number 2793780


Registered Office:

Victrex Technology Centre

Hillhouse International

Thornton Cleveleys

Lancashire FY5 4QD

United Kingdom


Tel: +44 (0) 1253 897700

Fax: +44 (0) 1253 897701

Web: www.victrex.com



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EAKSPFSANEFE

Companies

Victrex plc (VCT)
UK 100

Latest directors dealings